In the latest trading session, 0.72 million Citius Pharmaceuticals Inc (NASDAQ:CTXR) shares changed hands as the company’s beta touched 1.61. With the company’s most recent per share price at $0.47 changed hands at -$0.03 or -6.15% at last look, the market valuation stands at $84.90M. CTXR’s current price is a discount, trading about -127.66% off its 52-week high of $1.07. The share price had its 52-week low at $0.48, which suggests the last value was -2.13% down since then. When we look at Citius Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.19 million shares, with the 3-month average coming to 1.90 million.
Analysts gave the Citius Pharmaceuticals Inc (CTXR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CTXR as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Citius Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.04.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Citius Pharmaceuticals Inc (NASDAQ:CTXR) trade information
Instantly CTXR was in red as seen in intraday trades today. With action -13.00%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -37.90%, with the 5-day performance at -13.00% in the red. However, in the 30-day time frame, Citius Pharmaceuticals Inc (NASDAQ:CTXR) is -17.58% down. Looking at the short shares, we see there were 12.53 million shares sold at short interest cover period of 11.76 days.
Citius Pharmaceuticals Inc (CTXR) estimates and forecasts
Data shows that the Citius Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -51.89% over the past 6 months, a 12.50% in annual growth rate that is considerably lower than the industry average of 20.00%.
2 analysts are of the opinion that Citius Pharmaceuticals Inc’s revenue for the current quarter will be 15.87M. The estimates for the next quarter sales put growth at -25.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 28.21%. The 2024 estimates are for Citius Pharmaceuticals Inc earnings to increase by 2.27%.
CTXR Dividends
Citius Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2024-Dec-27.
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.81% of Citius Pharmaceuticals Inc shares while 17.00% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 18.24%. There are 17.00% institutions holding the Citius Pharmaceuticals Inc stock share, with ARMISTICE CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 6.3845% of the shares, roughly 10.16 million CTXR shares worth $5.93 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 3.9776% or 6.33 million shares worth $3.69 million as of 2024-06-30.
